NIOPEG
PEGFILGRASTIM BIOSIMILAR
APPROVED BY HEALTH CANADA
Nora Innovation is proud to introduce the first biosimilar in its product line.
NIOPEG (PEGFILGRASTIM)
Niopeg is prescribed for non-myeloid cancer patients treated with myelosuppressive anti-cancer agents and presenting a potential risk of febrile neutropenia. The aim is to reduce the risk of infections associated with this condition. Niopeg works by increasing the number of neutrophils, the white blood cells essential for fighting infection.
CONSULT ALL THE INFORMATION
AND DOCUMENTS RELATED TO YOUR PROFILE.
ABOUT NORA INNOVATION
Nora Innovation, a division of Nora Pharma, offers a support program designed to provide patients and healthcare professionals with a clear and accessible user experience, designed to offer effective approaches to meeting a variety of needs. Nora Innovation is committed to supporting patients at every stage of their healthcare journey.
NORACOMPANION PATIENT SUPPORT PROGRAM
Sign up for full support!
ONLINE
You can register directly at
accessapsp.ca for easy access to the program.
WITH THE HELP OF YOUR PHARMACIST
If you prefer, your pharmacist can also
register you and manage the process for you.
NIOPEG
A full range of services at your disposal
FREQUENTLY ASKED QUESTIONS
ADMINISTRATION
As a single dose in each
chemotherapy cycle.
SPACING WITH CHEMO
24 hours after chemo and 14 days before the next cycle
OMITTED DOSES
Administer if the next cycle
is more than 14 days away.
AGITATION
Niopeg should not be
shaken vigorously.
ABOUT NORA INNOVATION
Nora Innovation, a division of Nora Pharma, offers a support program designed to provide patients and healthcare professionals with a clear and accessible user experience, designed to offer effective approaches to meeting a variety of needs. Nora Innovation is committed to supporting patients at every stage of their healthcare journey.